Barclays reissued their sell rating on shares of Genomic Health (NASDAQ:GHDX) in a research note issued to investors on Monday. The brokerage currently has a $28.00 price target on the medical research company’s stock.
Several other analysts also recently issued reports on the company. Zacks Investment Research downgraded Genomic Health from a hold rating to a sell rating in a research report on Wednesday, October 4th. Canaccord Genuity restated a buy rating and issued a $35.00 price objective on shares of Genomic Health in a research report on Wednesday, September 27th. Jefferies Group restated a hold rating and issued a $33.00 price objective on shares of Genomic Health in a research report on Thursday, September 14th. William Blair downgraded Genomic Health from an outperform rating to a market perform rating in a research report on Wednesday, December 20th. Finally, BidaskClub upgraded Genomic Health from a sell rating to a hold rating in a research report on Tuesday, December 19th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the company’s stock. The stock has an average rating of Hold and an average target price of $31.71.
Genomic Health (NASDAQ GHDX) traded up $0.27 during trading on Monday, reaching $35.49. The company’s stock had a trading volume of 207,523 shares, compared to its average volume of 209,317. The firm has a market capitalization of $1,230.00, a price-to-earnings ratio of -273.00 and a beta of 0.65. Genomic Health has a 12 month low of $26.37 and a 12 month high of $37.50.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Aurora Investment Counsel purchased a new position in Genomic Health during the fourth quarter worth about $1,879,000. Public Employees Retirement System of Ohio purchased a new position in Genomic Health during the third quarter worth about $444,000. GSA Capital Partners LLP lifted its position in Genomic Health by 43.7% during the third quarter. GSA Capital Partners LLP now owns 63,100 shares of the medical research company’s stock worth $2,025,000 after buying an additional 19,200 shares during the period. Cubist Systematic Strategies LLC purchased a new position in Genomic Health during the third quarter worth about $138,000. Finally, Point72 Asset Management L.P. purchased a new position in Genomic Health during the third quarter worth about $350,000. Hedge funds and other institutional investors own 89.67% of the company’s stock.
Genomic Health Company Profile
Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.